FDA accepts Teva's application for Uzedy for bipolar I disorder
Source: SeekingAlpha
2025-02-25 16:52:37 ET
More on Teva Pharmaceutical
- Teva Pharmaceutical Industries Limited (TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference (Transcript)
- Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
- Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript
- Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara
- Corcept accused in California of stifling Teva’s generic launch
Read the full article on Seeking Alpha
For further details see:
FDA accepts Teva's application for Uzedy for bipolar I disorder
Medical Intelligence Technologies Inc
NASDAQ: MDCLF
MDCLF Trading
100.0% G/L:
$6.9757 Last:
2,000 Volume:
$0 Open:
MDCLF Latest News
May 28, 2026 12:11:00 pm
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
November 11, 2025 02:00:00 am
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
November 10, 2025 12:00:00 pm
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
